SG11201408791TA - Dihydropyrimidine compounds and their application in pharmaceuticals - Google Patents
Dihydropyrimidine compounds and their application in pharmaceuticalsInfo
- Publication number
- SG11201408791TA SG11201408791TA SG11201408791TA SG11201408791TA SG11201408791TA SG 11201408791T A SG11201408791T A SG 11201408791TA SG 11201408791T A SG11201408791T A SG 11201408791TA SG 11201408791T A SG11201408791T A SG 11201408791TA SG 11201408791T A SG11201408791T A SG 11201408791TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- dongguan
- dongyangguang
- zhen
- guangdong
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 February 2014 (27.02.2014) WIPOIPCT (10) International Publication Number WO 2014/029193 A1 (51) International Patent Classification: C07D 401/00 (2006.01) C07D 401/14 (2006.01) C07D 401/04 (2006.01) C07D 413/14 (2006.01) C07D 417/14 (2006.01) C07D 409/14 (2006.01) C07D 407/14 (2006.01) C07D 405/14 (2006.01) C07D 403/14 (2006.01) A61K31/506 (2006.01) A61K31/505 (2006.01) A61P 31/12 (2006.01) (21) International Application Number: PCT/CN2013/001001 23 August 2013 (23.08.2013) (22) International Filing Date: (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201210303033.4 24 August 2012 (24.08.2012) CN 201310116949.3 3 April 2013 (03.04.2013) CN (71) Applicant: SUNSHINE LAKE PHARMA CO., LTD. [CN/CN]; LIN, Taoxi, Northern Industrial Area, Songshan Lake, Dongguan, Guangdong (CN). (72) Inventors: ZHANG, Yingjun; Dongyangguang Hi-tech Park, Zhen An Road No.368, Shang Sha, Chang An Town, Dongguan, Guangdong 523871 (CN). REN, Qingyun; Dongyangguang Hi-tech Park, Zhen An Road No.368, Shang Sha, Chang An Town, Dongguan, Guangdong 523871 (CN). LIU, Xinchang; Dongyangguang Hi-tech Park, Zhen An Road No.368, Shang Sha, Chang An Town, Dongguan, Guangdong 523871 (CN). SIEGFRIED, Gold- mann; Dongyangguang Hi-tech Park, Zhen An Road No.368, Shang Sha, Chang An Town, Dongguan, Guang dong 523871 (CN). (74) Agent: CN-KNOWHOW INTELLECTUAL PROP ERTY AGENT LIMITED; 18th Floor, Tower B, CEC Plaza, No.3 Dan Ling Street, Haidian District, Beijing 100080 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS o\ i-H o\ CJ o o CJ o & N R 4 (I) O R 1 '\"Yi* (la) (57) Abstract: Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically,provided herein are compounds having Formula (I) or (la), or an enantiomer, a diastereoisomer, tautomer, hydrate, solvate, a a a or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (la), or an enantiomer, a diastereoisomer, tautomer, a a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV dis -
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210303033 | 2012-08-24 | ||
| CN201310116949 | 2013-04-03 | ||
| PCT/CN2013/001001 WO2014029193A1 (en) | 2012-08-24 | 2013-08-23 | Dihydropyrimidine compounds and their application in pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408791TA true SG11201408791TA (en) | 2015-01-29 |
Family
ID=50149385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408791TA SG11201408791TA (en) | 2012-08-24 | 2013-08-23 | Dihydropyrimidine compounds and their application in pharmaceuticals |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9340538B2 (en) |
| EP (1) | EP2888241B1 (en) |
| JP (1) | JP6263533B2 (en) |
| KR (1) | KR102148678B1 (en) |
| CN (2) | CN104926808B (en) |
| AU (1) | AU2013305390C1 (en) |
| BR (1) | BR112015002858A2 (en) |
| CA (1) | CA2876690C (en) |
| DK (1) | DK2888241T3 (en) |
| ES (1) | ES2640049T3 (en) |
| HK (1) | HK1206027A1 (en) |
| HU (1) | HUE034919T2 (en) |
| MX (1) | MX2015002511A (en) |
| MY (1) | MY182403A (en) |
| PL (1) | PL2888241T3 (en) |
| PT (1) | PT2888241T (en) |
| RU (1) | RU2655914C9 (en) |
| SG (1) | SG11201408791TA (en) |
| TW (1) | TWI668217B (en) |
| WO (1) | WO2014029193A1 (en) |
| ZA (1) | ZA201500451B (en) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| CA2881322A1 (en) * | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| CN103664899B (en) * | 2012-09-11 | 2017-06-16 | 广东东阳光药业有限公司 | The Dihydropyrimidines of heteroaryl substitution and its application in medicine |
| CN104650069B (en) * | 2013-11-19 | 2019-04-19 | 广东东阳光药业有限公司 | 4- methyl Dihydropyrimidines and its application in drug |
| AU2014352404B2 (en) * | 2013-11-19 | 2018-07-19 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
| JP6434511B2 (en) | 2013-11-27 | 2018-12-05 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | Method for producing dihydropyrimidine derivatives and intermediates thereof |
| EA030115B9 (en) * | 2014-03-07 | 2018-09-28 | Ф. Хоффманн-Ля Рош Аг | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| US9771358B2 (en) | 2014-03-28 | 2017-09-26 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and their application in pharmaceuticals |
| JP6710642B2 (en) * | 2014-05-30 | 2020-06-17 | チル ファーマシューティカル カンパニー リミテッド | Dihydropyrimidine fused ring derivative as HBV inhibitor |
| CN105153164B (en) * | 2014-05-30 | 2018-10-30 | 齐鲁制药有限公司 | Dihydro-pyrimidin and ring derivatives as HBV inhibitor |
| WO2016012470A1 (en) * | 2014-07-25 | 2016-01-28 | F. Hoffmann-La Roche Ag | New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid |
| EP3253751B1 (en) * | 2015-02-07 | 2020-12-09 | Sunshine Lake Pharma Co., Ltd. | Complexes and salts of dihydropyrimidine derivatives and their application in pharmaceuticals |
| SG10201912847QA (en) | 2015-03-16 | 2020-02-27 | Hoffmann La Roche | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
| US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| WO2017011552A1 (en) | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| BR112018009009A8 (en) * | 2015-11-03 | 2019-02-26 | Hoffmann La Roche | combined therapy of an hbv capsid formation inhibitor and an interferon |
| US10280175B2 (en) | 2016-02-02 | 2019-05-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| AR107633A1 (en) | 2016-02-19 | 2018-05-16 | Hoffmann La Roche | PROCEDURE FOR THE PREPARATION OF ACID 4-PHENYL-5-ALCOXICARBONIL-2-TIAZOL-2-IL-1,4-DIHYDROPIRIMIDIN-6-IL- [METHYL] -3-OXO-5,6,8,8A-TETRAHIDRO- 1H-IMIDAZO [1,5A] PIRAZIN-2-IL-CARBOXYL |
| ES2938341T3 (en) | 2016-03-07 | 2023-04-10 | Enanta Pharm Inc | Antiviral agents against hepatitis B |
| CN107400125B (en) * | 2016-05-19 | 2020-02-11 | 广东东阳光药业有限公司 | Crystal form, salt and compound of dihydropyrimidine derivative and application thereof in medicines |
| SG11201810834WA (en) * | 2016-06-10 | 2018-12-28 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| CN107674072B (en) * | 2016-08-01 | 2020-11-24 | 广东东阳光药业有限公司 | Process for producing dihydropyrimidine derivative and acid adduct thereof |
| WO2018036941A1 (en) | 2016-08-24 | 2018-03-01 | F. Hoffmann-La Roche Ag | Combination therapy of an hbv capsid assembly inhibitor and a nucleos(t)ide analogue |
| CN107793409B (en) * | 2016-09-05 | 2022-09-27 | 广东东阳光药业有限公司 | Dihydropyrimidine compound and application thereof in medicine |
| CN109803967B (en) * | 2016-09-09 | 2022-05-24 | 浙江海正药业股份有限公司 | Dihydropyrimidine compound and preparation method and application thereof |
| PL3508483T3 (en) * | 2016-11-18 | 2022-02-07 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Dihydropyrimidine compound and preparation method and use thereof |
| US11166954B2 (en) | 2016-11-18 | 2021-11-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Dihydropyrimidine compound and preparation method and use thereof |
| WO2019001420A1 (en) | 2017-06-27 | 2019-01-03 | Janssen Pharmaceutica Nv | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections |
| CA3070004A1 (en) | 2017-07-27 | 2019-01-31 | Jiangsu Hengrui Medicine Co., Ltd. | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine |
| EA202090514A1 (en) | 2017-08-28 | 2020-06-24 | Энанта Фармасьютикалс, Инк. | ANTI-VIRAL AGAINST HEPATITIS IN |
| IL297543A (en) * | 2017-11-30 | 2022-12-01 | Arrakis Therapeutics Inc | Nucleic acid-binding photoprobes and uses thereof |
| US10723733B2 (en) | 2017-12-06 | 2020-07-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| TW201927789A (en) | 2017-12-06 | 2019-07-16 | 美商因那塔製藥公司 | Hepatitis B antiviral agents |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US10729688B2 (en) | 2018-03-29 | 2020-08-04 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| AU2019266729A1 (en) * | 2018-05-08 | 2021-03-11 | Janssen Sciences Ireland Unlimited Company | Dihydropyrimidine derivatives and uses thereof in the treatment of HBV infection or of HBV-induced diseases |
| CA3099605A1 (en) * | 2018-06-26 | 2020-01-02 | Janssen Sciences Ireland Unlimited Company | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases |
| CN108947996B (en) * | 2018-07-12 | 2022-01-18 | 山东大学 | Dihydropyrimidine-sulfonamide derivative and preparation method and application thereof |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| US10865211B2 (en) | 2018-09-21 | 2020-12-15 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2020087107A1 (en) | 2018-10-31 | 2020-05-07 | The University Of Sydney | Compositions and methods for treating viral infections |
| CN109251201B (en) * | 2018-11-03 | 2020-06-02 | 深圳市第二人民医院 | anti-HBV nitrogen-containing heterocyclic compound |
| CN109232555B (en) * | 2018-11-03 | 2020-06-02 | 深圳市第二人民医院 | anti-HBV oxygen-containing heterocyclic compound |
| KR20210093951A (en) | 2018-11-21 | 2021-07-28 | 이난타 파마슈티칼스, 인코포레이티드 | Functionalized Heterocycles as Antiviral Agents |
| WO2020193459A1 (en) | 2019-03-25 | 2020-10-01 | F. Hoffmann-La Roche Ag | Solid forms of a compound of hbv core protein allosteric modifier |
| CN114072407A (en) | 2019-04-02 | 2022-02-18 | 阿里戈斯治疗公司 | Compounds targeting PRMT5 |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US20220249647A1 (en) * | 2019-06-18 | 2022-08-11 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
| CN110204539B (en) * | 2019-07-03 | 2021-07-23 | 山东大学 | Dihydropyrimidine prodrug and preparation method and application thereof |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| AU2020323092A1 (en) * | 2019-07-31 | 2022-03-24 | Janssen Sciences Ireland Unlimited Company | Dihydropyrimidine derivatives and uses thereof in the treatment of HBV infection or of HBV-induced diseases |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| KR20220119666A (en) * | 2019-12-20 | 2022-08-30 | 얀센 파마슈티카 엔.브이. | Heteroaryldihydropyrimidine derivatives and methods of treatment of hepatitis B infection |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| WO2022052923A1 (en) * | 2020-09-08 | 2022-03-17 | 和博医药有限公司 | Dihydropyrimidine compound and application thereof |
| UY39616A (en) | 2021-01-29 | 2022-07-29 | Janssen Sciences Ireland Unlimited Co | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES |
| JP2024505709A (en) * | 2021-02-05 | 2024-02-07 | ヘパジーン セラピューティクス（エイチケー）リミティド | Phenyldihydropyrimidine compounds and their uses |
| WO2022257942A1 (en) | 2021-06-09 | 2022-12-15 | Janssen Sciences Ireland Unlimited Company | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0202654A3 (en) | 1985-05-20 | 1987-12-16 | E.R. Squibb & Sons, Inc. | 5-carboxy-1,4-dihydropyrimidine derivatives |
| GB8906168D0 (en) | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
| CA2154633A1 (en) * | 1995-01-25 | 1996-07-26 | Paul Harry Sandstrom | Silica reinforced rubber composition and use in tires |
| SE9702563D0 (en) | 1997-07-02 | 1997-07-02 | Astra Ab | Compounds |
| SE9702564D0 (en) | 1997-07-02 | 1997-07-02 | Astra Ab | New compounds |
| DE19817264A1 (en) * | 1998-04-18 | 1999-10-21 | Bayer Ag | New dihydropyrimidine derivatives and their corresponding mesomers useful as antiviral agents |
| DE19817262A1 (en) * | 1998-04-18 | 1999-10-21 | Bayer Ag | New dihydropyrimidine derivatives and their corresponding mesomers useful in treatment of hepatitis |
| DE19817265A1 (en) | 1998-04-18 | 1999-10-21 | Bayer Ag | Treating hepatitis B using new or known dihydropyrimidine derivative antiviral agents |
| WO2000058302A1 (en) | 1999-03-25 | 2000-10-05 | Bayer Aktiengesellschaft | Dihydropyrimidines and their use in the treatment of hepatitis b |
| DE10012549A1 (en) | 2000-03-15 | 2001-09-20 | Bayer Ag | New heterocyclic-substituted dihydropyrimidine derivatives useful for treatment of viral infections, especially hepatitis B infections |
| DE10012823A1 (en) * | 2000-03-16 | 2001-09-20 | Bayer Ag | New alkyl-6-aminoalkyl-dihydropyrimidine-5-carboxylate derivatives, useful for the treatment of viral, especially hepatitis B, infections |
| DE10012824A1 (en) | 2000-03-16 | 2001-09-20 | Bayer Ag | New 6-hydroxyhydrocarbyl or 6-thiohydrocarbyl-dihydropyrimidine-5-carboxylic acid derivatives, useful for the treatment of viral infections, especially hepatitis B infections |
| DE10013126A1 (en) * | 2000-03-17 | 2001-09-20 | Bayer Ag | New 6-aminoalkyl-dihydropyrimidine-5-carboxylate ester derivatives, useful as antiviral agents having strong activity against hepatitis B virus and low cytotoxicity |
| DE10013125A1 (en) | 2000-03-17 | 2001-09-20 | Bayer Ag | New 4-dihalophenyl-dihydropyrimidine-5-carboxylate ester derivatives, useful as antiviral agents having strong activity against hepatitis B virus and low cytotoxicity |
| WO2005007124A2 (en) | 2003-07-23 | 2005-01-27 | Bristol-Myers Squibb Company | Substituted dihydropyrimidine inhibitors of calcium channel function |
| PE20110118A1 (en) * | 2005-10-04 | 2011-03-08 | Aventis Pharma Inc | PYRIMIDINE AMIDE COMPOUNDS AS INHIBITORS OF PGDS |
| CN101104617B (en) | 2006-07-10 | 2010-06-23 | 北京摩力克科技有限公司 | Dihydropyrimidine compounds and use of the same in preparing medicament for curing and preventing virosis |
| CN101104604B (en) | 2006-07-10 | 2011-03-02 | 北京摩力克科技有限公司 | Optically pure dihydropyrimidine compounds and use for the same in preparing medicament for curing and preventing virosis |
| WO2008024692A1 (en) | 2006-08-23 | 2008-02-28 | Neurogen Corporation | N-oxide aryl sulfones and sulfoxides |
| CN101225084A (en) | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | Dihydropyrimidine compound and use thereof in preparation of medicine treating and preventing virus diseases |
| PT2159224E (en) | 2007-06-18 | 2012-10-24 | Sunshine Lake Pharma Co Ltd | Bromo-phenyl substituted thiazolyl dihydropyrimidines |
| CN101328169B (en) * | 2007-06-18 | 2011-05-25 | 张中能 | Diethylcarbamyl-substituted thiazole dihydropyrimidine |
| WO2008154820A1 (en) | 2007-06-18 | 2008-12-24 | Zhang, Zhongneng | Carbethoxy-substituted thiazolyl dihydropyrimidines |
| CN101328170B (en) * | 2007-06-18 | 2011-09-14 | 张中能 | Fluorophenyl-substituted thiazole dihydropyrimidine |
| CN101744823B (en) * | 2008-12-17 | 2013-06-19 | 广东东阳光药业有限公司 | Solid dispersion of dihydropyrimidine compounds and preparation thereof for medical purpose |
| WO2010069147A1 (en) * | 2008-12-17 | 2010-06-24 | 张中能 | Dihydropyrimidine derivatives, compositions thereof and their use |
| CN101575318B (en) * | 2009-06-25 | 2012-02-08 | 中国人民解放军军事医学科学院毒物药物研究所 | Novel dihydropyridine compound and application thereof on preparing drugs for curing and/or preventing virus diseases |
| US9968650B2 (en) | 2011-07-13 | 2018-05-15 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
| US9487534B2 (en) | 2011-08-02 | 2016-11-08 | Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California | Modulators of virus assembly as antiviral agents |
| CN104302626B (en) | 2012-01-06 | 2016-09-07 | 爱尔兰詹森科学公司 | 4,4-dibasic-1,4-dihydro-pyrimidin and the purposes of the medicine as treatment hepatitis B thereof |
| US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| CA2881322A1 (en) * | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
-
2013
- 2013-08-23 CN CN201510324031.7A patent/CN104926808B/en active Active
- 2013-08-23 JP JP2015527761A patent/JP6263533B2/en active Active
- 2013-08-23 RU RU2015110082A patent/RU2655914C9/en active
- 2013-08-23 MX MX2015002511A patent/MX2015002511A/en unknown
- 2013-08-23 SG SG11201408791TA patent/SG11201408791TA/en unknown
- 2013-08-23 PT PT138305537T patent/PT2888241T/en unknown
- 2013-08-23 PL PL13830553T patent/PL2888241T3/en unknown
- 2013-08-23 AU AU2013305390A patent/AU2013305390C1/en active Active
- 2013-08-23 CN CN201310373003.5A patent/CN103626752B/en active Active
- 2013-08-23 BR BR112015002858A patent/BR112015002858A2/en active Search and Examination
- 2013-08-23 KR KR1020147036508A patent/KR102148678B1/en active IP Right Grant
- 2013-08-23 WO PCT/CN2013/001001 patent/WO2014029193A1/en active Application Filing
- 2013-08-23 US US14/416,061 patent/US9340538B2/en active Active
- 2013-08-23 HU HUE13830553A patent/HUE034919T2/en unknown
- 2013-08-23 CA CA2876690A patent/CA2876690C/en active Active
- 2013-08-23 ES ES13830553.7T patent/ES2640049T3/en active Active
- 2013-08-23 EP EP13830553.7A patent/EP2888241B1/en active Active
- 2013-08-23 MY MYPI2015700218A patent/MY182403A/en unknown
- 2013-08-23 TW TW102130355A patent/TWI668217B/en active
- 2013-08-23 DK DK13830553.7T patent/DK2888241T3/en active
-
2015
- 2015-01-22 ZA ZA2015/00451A patent/ZA201500451B/en unknown
- 2015-07-13 HK HK15106680.5A patent/HK1206027A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408791TA (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201909278SA (en) | Fungicidal oxadiazoles | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804223TA (en) | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| CA2859619C (en) | Bromodomain inhibitors | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201901658PA (en) | Beta-lactamase inhibitor compounds | |
| SG11201909615YA (en) | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201407402TA (en) | Carbazole-containing sulfonamides as cryptochrome modulators | |
| SG11201900689RA (en) | Compounds and compositions and uses thereof | |
| SG11201407988UA (en) | Process for improved opioid synthesis |